Propofol induces proliferation partially via downregulation of p53 protein and promotes migration via activation of the Nrf2 pathway in human breast cancer cell line MDA-MB-231

Meng,Chao; Song,Linlin; Wang,Juan; Li,Di; Liu,Yanhong; Cui,Xiaoguang

doi:10.3892/or.2016.5332

Propofol induces proliferation partially via downregulation of p53 protein and promotes migration via activation of the Nrf2 pathway in human breast cancer cell line MDA-MB-231

Authors:
- Chao Meng
- Linlin Song
- Juan Wang
- Di Li
- Yanhong Liu
- Xiaoguang Cui
View Affiliations

Affiliations: Department of Anesthesiology, The Second Affiliated Hospital of Harbin Medical University, and Hei Long Jiang Province Key Laboratory of Research on Anesthesiology and Critical Care Medicine, Harbin, Heilongjiang 150001, P.R. China
Published online on: December 23, 2016 https://doi.org/10.3892/or.2016.5332
Pages: 841-848

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Antioxidants induce the proliferation of cancers by decreasing the expression of p53. Propofol, one of the most extensively used intravenous anesthetics, provides its antioxidative activity via activation of the nuclear factor E2-related factor-2 (Nrf2) pathway, but the mechanisms involved in the effects remain unknown. Thus, we aimed to investigate the function of p53 and Nrf2 in the human breast cancer cell line MDA-MB-231 following treatment with propofol. The cells were treated with propofol (2, 5 and 10 µg/ml) for 1, 4 and 12 h, and MTT assay was used to evaluate cell proliferation, and a wound healing assay was used to evaluate cell migration. Cell apoptosis, caspase-3 activity, and western blot analysis for p53 and Nrf2 protein were also assessed. Finally, PIK-75, a potent Nrf2 inhibitor, was used to confirm the effects of Nrf2 after treatment with propofol. Treatment of MDA-MB‑231 cells with propofol resulted in increased proliferation and migration in a dose- and time-dependent manner. After treatment with propofol for 12 h, the Nrf2 protein expression was increased, while the percentage of apoptotic cells, caspase-3 activity, and expression of p53 were significantly decreased. Additionally, treatment with the Nrf2 inhibitor increased the percentage of apoptotic cells, inhibited the migration almost completely, and decreased the degree of proliferation, while the expression of p53 was not affected. In conclusion, propofol increased the proliferation of human breast cancer MDA-MB‑231 cells, which was at least partially associated with the inhibition of the expression of p53, and induced cell migration, which was involved in the activation of the Nrf2 pathway.

View Figures

View References

1	Choi YK, Por ED, Kwon YG and Kim YM: Regulation of ROS production and vascular function by carbon monoxide. Oxid Med Cell Longev. 2012:7942372012. View Article : Google Scholar : PubMed/NCBI
2	Clarke MW, Burnett JR and Croft KD: Vitamin E in human health and disease. Crit Rev Clin Lab Sci. 45:417–450. 2008. View Article : Google Scholar : PubMed/NCBI
3	Rayman MP: Selenium and human health. Lancet. 379:1256–1268. 2012. View Article : Google Scholar : PubMed/NCBI
4	Serafini M, Bellocco R, Wolk A and Ekström AM: Total antioxidant potential of fruit and vegetables and risk of gastric cancer. Gastroenterology. 123:985–991. 2002. View Article : Google Scholar : PubMed/NCBI
5	Kong Q and Lillehei KO: Antioxidant inhibitors for cancer therapy. Med Hypotheses. 51:405–409. 1998. View Article : Google Scholar : PubMed/NCBI
6	Sayin VI, Ibrahim MX, Larsson E, Nilsson JA, Lindahl P and Bergo MO: Antioxidants accelerate lung cancer progression in mice. Sci Transl Med. 6:221ra15. 2014. View Article : Google Scholar : PubMed/NCBI
7	Wolff S, Erster S, Palacios G and Moll UM: p53's mitochondrial translocation and MOMP action is independent of Puma and Bax and severely disrupts mitochondrial membrane integrity. Cell Res. 18:733–744. 2008. View Article : Google Scholar : PubMed/NCBI
8	Leu JI, Dumont P, Hafey M, Murphy ME and George DL: Mitochondrial p53 activates Bak and causes disruption of a Bak-Mcl1 complex. Nat Cell Biol. 6:443–450. 2004. View Article : Google Scholar : PubMed/NCBI
9	Marik PE: Propofol: Therapeutic indications and side-effects. Curr Pharm Des. 10:3639–3649. 2004. View Article : Google Scholar : PubMed/NCBI
10	Zhang L, Wang N, Zhou S, Ye W, Jing G and Zhang M: Propofol induces proliferation and invasion of gallbladder cancer cells through activation of Nrf2. J Exp Clin Cancer Res. 31:662012. View Article : Google Scholar : PubMed/NCBI
11	Xu YB, Du QH, Zhang MY, Yun P and He CY: Propofol suppresses proliferation, invasion and angiogenesis by down-regulating ERK-VEGF/MMP-9 signaling in Eca-109 esophageal squamous cell carcinoma cells. Eur Rev Med Pharmacol Sci. 17:2486–2494. 2013.PubMed/NCBI
12	Duong HQ, Yi YW, Kang HJ, Hong YB, Tang W, Wang A, Seong YS and Bae I: Inhibition of NRF2 by PIK-75 augments sensitivity of pancreatic cancer cells to gemcitabine. Int J Oncol. 44:959–969. 2014.PubMed/NCBI
13	Chakraborty S, Mazumdar M, Mukherjee S, Bhattacharjee P, Adhikary A, Manna A, Chakraborty S, Khan P, Sen A and Das T: Restoration of p53/miR-34a regulatory axis decreases survival advantage and ensures Bax-dependent apoptosis of non-small cell lung carcinoma cells. FEBS Lett. 588:549–559. 2014. View Article : Google Scholar : PubMed/NCBI
14	Moll UM, Marchenko N and Zhang XK: p53 and Nur77/TR3-transcription factors that directly target mitochondria for cell death induction. Oncogene. 25:4725–4743. 2006. View Article : Google Scholar : PubMed/NCBI
15	Sayin VI, Khan OM, Pehlivanoglu LE, Staffas A, Ibrahim MX, Asplund A, Agren P, Nilton A, Bergström G, Bergo MO, et al: Loss of one copy of Zfp148 reduces lesional macrophage proliferation and atherosclerosis in mice by activating p53. Circ Res. 115:781–789. 2014. View Article : Google Scholar : PubMed/NCBI
16	Moi P, Chan K, Asunis I, Cao A and Kan YW: Isolation of NF-E2-related factor 2 (Nrf2), a NF-E2-like basic leucine zipper transcriptional activator that binds to the tandem NF-E2/AP1 repeat of the beta-globin locus control region. Proc Natl Acad Sci USA. 91:9926–9930. 1994. View Article : Google Scholar : PubMed/NCBI
17	Maher J and Yamamoto M: The rise of antioxidant signaling - the evolution and hormetic actions of Nrf2. Toxicol Appl Pharmacol. 244:4–15. 2010. View Article : Google Scholar : PubMed/NCBI
18	Jaramillo MC and Zhang DD: The emerging role of the Nrf2-Keap1 signaling pathway in cancer. Genes Dev. 27:2179–2191. 2013. View Article : Google Scholar : PubMed/NCBI
19	Hsu HT, Tseng YT, Hsu YY, Cheng KI, Chou SH and Lo YC: Propofol attenuates lipopolysaccharide-induced reactive oxygen species production through activation of Nrf2/GSH and suppression of NADPH oxidase in human alveolar epithelial cells. Inflammation. 38:415–423. 2015. View Article : Google Scholar : PubMed/NCBI
20	Chen J, Zhao WH, Song ZJ, Chen HG, Xie KL, Zhao XX and Lei GY: Effects of propofol on proliferation and apoptosis of HCC827 cells. Journal of Xi'an Jiaotong University (Medical Sciences). 3:361–363, 384. 2014.[(In Chinese)].
21	Zhang M, Zhang C, Zhang L, Yang Q, Zhou S, Wen Q and Wang J: Nrf2 is a potential prognostic marker and promotes proliferation and invasion in human hepatocellular carcinoma. BMC Cancer. 15:5312015. View Article : Google Scholar : PubMed/NCBI
22	Pan H, Wang H, Zhu L, Mao L, Qiao L and Su X: The role of Nrf2 in migration and invasion of human glioma cell U251. World Neurosurg. 80:363–370. 2013. View Article : Google Scholar : PubMed/NCBI
23	Wang J, Zhang M, Zhang L, Cai H, Zhou S, Zhang J and Wang Y: Correlation of Nrf2, HO-1, and MRP3 in gallbladder cancer and their relationships to clinicopathologic features and survival. J Surg Res. 164:e99–e105. 2010. View Article : Google Scholar : PubMed/NCBI
24	Ma RQ, Zhang MX, Wang JS, Cai H, Yeer MK and Duan XY: Expression and distribution of Nrf2 in several hepatocellular carcinoma cell lines. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 27:608–610. 2011.(In Chinese). PubMed/NCBI
25	Mao JT, Tangsakar E, Shen H, Wang ZQ, Zhang MX, Chen JX, Zhang G and Wang JS: Expression and clinical significance of Nrf2 in esophageal squamous cell carcinoma. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 27:1231–1233. 2011.(In Chinese). PubMed/NCBI
26	Zhou S, Ye W, Shao Q, Zhang M and Liang J: Nrf2 is a potential therapeutic target in radioresistance in human cancer. Crit Rev Oncol Hematol. 88:706–715. 2013. View Article : Google Scholar : PubMed/NCBI
27	Kesharwani P, Gajbhiye V and Jain NK: A review of nanocarriers for the delivery of small interfering RNA. Biomaterials. 33:7138–7150. 2012. View Article : Google Scholar : PubMed/NCBI
28	Garib V, Niggemann B, Zänker KS, Brandt L and Kubens BS: Influence of non-volatile anesthetics on the migration behavior of the human breast cancer cell line MDA-MB-468. Acta Anaesthesiol Scand. 46:836–844. 2002. View Article : Google Scholar : PubMed/NCBI
29	Garib V, Lang K, Niggemann B, Zänker KS, Brandt L and Dittmar T: Propofol-induced calcium signalling and actin reorganization within breast carcinoma cells. Eur J Anaesthesiol. 22:609–615. 2005. View Article : Google Scholar : PubMed/NCBI
30	Li Q, Zhang L, Han Y, Jiang Z and Wang Q: Propofol reduces MMPs expression by inhibiting NF-κB activity in human MDA-MB-231 cells. Biomed Pharmacother. 66:52–56. 2012. View Article : Google Scholar : PubMed/NCBI
31	Ecimovic P, Murray D, Doran P and Buggy DJ: Propofol and bupivacaine in breast cancer cell function in vitro - role of the NET1 gene. Anticancer Res. 34:1321–1331. 2014.PubMed/NCBI
32	Siddiqui RA, Zerouga M, Wu M, Castillo A, Harvey K, Zaloga GP and Stillwell W: Anticancer properties of propofol-docosahexaenoate and propofol-eicosapentaenoate on breast cancer cells. Breast Cancer Res. 7:R645–R654. 2005. View Article : Google Scholar : PubMed/NCBI
33	Deegan CA, Murray D, Doran P, Ecimovic P, Moriarty DC and Buggy DJ: Effect of anaesthetic technique on oestrogen receptor-negative breast cancer cell function in vitro. Br J Anaesth. 103:685–690. 2009. View Article : Google Scholar : PubMed/NCBI
34	Belouchi NE, Roux E, Savineau JP and Marthan R: Interaction of extracellular albumin and intravenous anaesthetics, etomidate and propofol, on calcium signalling in rat airway smooth muscle cells. Fundam Clin Pharmacol. 14:395–400. 2000. View Article : Google Scholar : PubMed/NCBI
35	Cui WY, Liu Y, Zhu YQ, Song T and Wang QS: Propofol induces endoplasmic reticulum (ER) stress and apoptosis in lung cancer cell H460. Tumour Biol. 35:5213–5217. 2014. View Article : Google Scholar : PubMed/NCBI